Inhibition of Angiogenesis‐Relevant Receptor Tyrosine Kinases by Sulindac Analogues | Zendy

Gourzoulidou Eleni | Zendy; Carpintero Mercedes | Zendy; Baumhof Patrick | Zendy; Giannis Athanassios | Zendy; Waldmann Herbert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Inhibition of Angiogenesis‐Relevant Receptor Tyrosine Kinases by Sulindac Analogues

Author(s) -

Gourzoulidou Eleni,

Carpintero Mercedes,

Baumhof Patrick,

Giannis Athanassios,

Waldmann Herbert

Publication year - 2005

Publication title -

chembiochem

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.05

H-Index - 126

eISSN - 1439-7633

pISSN - 1439-4227

DOI - 10.1002/cbic.200400192

Subject(s) - sulindac , receptor tyrosine kinase , angiogenesis , chemistry , tyrosine kinase , kinase , pharmacology , receptor , receptor protein tyrosine kinases , biochemistry , cancer research , biology , nonsteroidal

It's in the blood . Analogues (see formula) of the non‐steroidal inflammatory drug Sulindac are potent and selective inhibitors of the angiogenesis‐related receptor tyrosine kinases VEGFR‐2 and ‐3, IGF1R, FGF1R and Tie‐2; this suggests a possible link between the antiangiogenic properties of Sulindac metabolites and kinase inhibition.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research